Literature DB >> 9447953

Down-regulation of glomerular matrix metalloproteinase-2 gene in human NIDDM.

D Del Prete1, F Anglani, M Forino, M Ceol, P Fioretto, R Nosadini, B Baggio, G Gambaro.   

Abstract

Regulation of mesangial matrix deposition is a dynamic phenomenon involving synthetic and degradative processes. The latter involve a number of matrix metalloproteinases (MMP) and tissue inhibitors of matrix metalloproteinases (TIMP). Experimental studies suggest that mesangial matrix degradation is inhibited in diabetic nephropathy, and that this phenomenon has a pathogenic role. The expression of genes for MMP2 and TIMP2 in human diabetic nephropathy was investigated. Reverse transcription polymerase chain reaction was carried out in microdissected glomeruli and tubulo-interstitium obtained from kidney biopsies. We studied 16 NIDDM patients, 5 patients with glomerulonephritis or chronic kidney transplant rejection, and 5 normal control subjects. Albumin excretion rate and renal histology for NIDDM patients were available. Contrary to TIMP2 which was expressed both in tubulo-interstitium and glomeruli in almost all renal biopsies, MMP2 gene down-regulation was observed in glomeruli from all NIDDM patients, irrespective of the albumin excretion rate, and of renal histology. In contrast, this gene was expressed in biopsies from other subjects (chi(2) = 20.6; p = 0.000). In conclusion, this study demonstrates that: 1) in glomeruli of NIDDM patients the MMP2 gene is down-regulated; 2) in biopsies of NIDDM patients the MMP2/TIMP2 pattern is peculiar for NIDDM; 3) the MMP2 gene down-regulation is observed in all NIDDM patients, irrespective of the level of albuminuria and of renal histology. MMP2 gene down-regulation seems to be a molecular epiphenomenon of diabetes, rather than a marker of diabetic nephropathy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9447953     DOI: 10.1007/s001250050848

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  22 in total

Review 1.  Autocrine and paracrine mechanisms in the early stages of diabetic nephropathy.

Authors:  G Pugliese; F Pricci; G Romeo; G Leto; L Amadio; C Iacobini; U Di Mario
Journal:  J Endocrinol Invest       Date:  1999-10       Impact factor: 4.256

Review 2.  Matrix metalloproteinases, a disintegrin and metalloproteinases, and a disintegrin and metalloproteinases with thrombospondin motifs in non-neoplastic diseases.

Authors:  Takayuki Shiomi; Vincent Lemaître; Jeanine D'Armiento; Yasunori Okada
Journal:  Pathol Int       Date:  2010-07       Impact factor: 2.534

3.  Evaluation of metalloprotease inhibitors on hypertension and diabetic nephropathy.

Authors:  Jan M Williams; Jin Zhang; Paula North; Steven Lacy; Michael Yakes; Annette Dahly-Vernon; Richard J Roman
Journal:  Am J Physiol Renal Physiol       Date:  2011-01-12

Review 4.  Rethinking glomerular basement membrane thickening in diabetic nephropathy: adaptive or pathogenic?

Authors:  Caroline B Marshall
Journal:  Am J Physiol Renal Physiol       Date:  2016-08-31

5.  Establishment of a diabetic mouse model with progressive diabetic nephropathy.

Authors:  Akari Inada; Kojiro Nagai; Hidenori Arai; Jun-ichi Miyazaki; Keiko Nomura; Hiroshi Kanamori; Shinya Toyokuni; Yuichiro Yamada; Susan Bonner-Weir; Gordon C Weir; Atsushi Fukatsu; Yutaka Seino
Journal:  Am J Pathol       Date:  2005-08       Impact factor: 4.307

6.  Methylglyoxal induces hyperpermeability of the blood-retinal barrier via the loss of tight junction proteins and the activation of matrix metalloproteinases.

Authors:  Junghyun Kim; Chan-Sik Kim; Yun Mi Lee; Kyuhyung Jo; So Dam Shin; Jin Sook Kim
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-01-17       Impact factor: 3.117

Review 7.  Soluble biglycan as a biomarker of inflammatory renal diseases.

Authors:  Louise Tzung-Harn Hsieh; Madalina-Viviana Nastase; Jinyang Zeng-Brouwers; Renato V Iozzo; Liliana Schaefer
Journal:  Int J Biochem Cell Biol       Date:  2014-08-01       Impact factor: 5.085

8.  Levels of urinary matrix metalloproteinase-9 (MMP-9) and renal injuries in patients with type 2 diabetic nephropathy.

Authors:  Kyoichi Tashiro; Ichiro Koyanagi; Ikko Ohara; Takamichi Ito; Akemi Saitoh; Satoshi Horikoshi; Yasuhiko Tomino
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

9.  Association of kidney structure-related gene variants with type 2 diabetes-attributed end-stage kidney disease in African Americans.

Authors:  Meijian Guan; Jun Ma; Jacob M Keaton; Latchezar Dimitrov; Poorva Mudgal; Mary Stromberg; Jason A Bonomo; Pamela J Hicks; Barry I Freedman; Donald W Bowden; Maggie C Y Ng
Journal:  Hum Genet       Date:  2016-07-26       Impact factor: 4.132

10.  Effect of losartan on the mRNA expressions of MT3-MMP and TIMP-2 in diabetic kidneys.

Authors:  He-Lin Ding; Ming-Tong Xu; Ying Guo; Long Chen; Shao-Ling Zhang; Feng Li; Zu-Zhi Fu
Journal:  Rev Diabet Stud       Date:  2006-02-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.